Class information for: |
Basic class information |
| ID | Publications | Average number of references |
Avg. shr. active ref. in WoS |
|---|---|---|---|
| 16421 | 589 | 28.0 | 47% |
Classes in level above (level 2) |
| ID, lev. above |
Publications | Label for level above |
|---|---|---|
| 2793 | 2583 | TUMOR DORMANCY//DORN VA MED//CONCOMITANT RESISTANCE |
Terms with highest relevance score |
| Rank | Term | Type of term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
|---|---|---|---|---|---|---|
| 1 | ANTIGEN SHEDDING | Author keyword | 2 | 36% | 1% | 5 |
| 2 | ADOPTIVE CHEMOIMMUNOTHERAPY | Author keyword | 2 | 67% | 0% | 2 |
| 3 | DRUG RESISTANT TUMORS | Author keyword | 2 | 67% | 0% | 2 |
| 4 | THYMIC IMMUNE REACTIVITY | Author keyword | 1 | 100% | 0% | 2 |
| 5 | ANTITUMOR CYTOTOXICITY | Author keyword | 1 | 33% | 1% | 3 |
| 6 | CUALTOS | Address | 1 | 30% | 1% | 3 |
| 7 | TUMOR BEARING RATS | Author keyword | 1 | 27% | 1% | 3 |
| 8 | LOW DOSE CHEMOTHERAPY | Author keyword | 1 | 13% | 1% | 6 |
| 9 | ADRYAMICIN | Author keyword | 1 | 50% | 0% | 1 |
| 10 | ANTITUMOR CTL ACTIVITY | Author keyword | 1 | 50% | 0% | 1 |
Web of Science journal categories |
Author Key Words |
| Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
LCSH search | Wikipedia search |
|---|---|---|---|---|---|---|---|
| 1 | ANTIGEN SHEDDING | 2 | 36% | 1% | 5 | Search ANTIGEN+SHEDDING | Search ANTIGEN+SHEDDING |
| 2 | ADOPTIVE CHEMOIMMUNOTHERAPY | 2 | 67% | 0% | 2 | Search ADOPTIVE+CHEMOIMMUNOTHERAPY | Search ADOPTIVE+CHEMOIMMUNOTHERAPY |
| 3 | DRUG RESISTANT TUMORS | 2 | 67% | 0% | 2 | Search DRUG+RESISTANT+TUMORS | Search DRUG+RESISTANT+TUMORS |
| 4 | THYMIC IMMUNE REACTIVITY | 1 | 100% | 0% | 2 | Search THYMIC+IMMUNE+REACTIVITY | Search THYMIC+IMMUNE+REACTIVITY |
| 5 | ANTITUMOR CYTOTOXICITY | 1 | 33% | 1% | 3 | Search ANTITUMOR+CYTOTOXICITY | Search ANTITUMOR+CYTOTOXICITY |
| 6 | TUMOR BEARING RATS | 1 | 27% | 1% | 3 | Search TUMOR+BEARING+RATS | Search TUMOR+BEARING+RATS |
| 7 | LOW DOSE CHEMOTHERAPY | 1 | 13% | 1% | 6 | Search LOW+DOSE+CHEMOTHERAPY | Search LOW+DOSE+CHEMOTHERAPY |
| 8 | ADRYAMICIN | 1 | 50% | 0% | 1 | Search ADRYAMICIN | Search ADRYAMICIN |
| 9 | ANTITUMOR CTL ACTIVITY | 1 | 50% | 0% | 1 | Search ANTITUMOR+CTL+ACTIVITY | Search ANTITUMOR+CTL+ACTIVITY |
| 10 | ANTITUMOR EFFECTORS | 1 | 50% | 0% | 1 | Search ANTITUMOR+EFFECTORS | Search ANTITUMOR+EFFECTORS |
Key Words Plus |
| Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
|---|---|---|---|---|---|
| 1 | LARGE MOPC 315 TUMOR | 6 | 50% | 2% | 9 |
| 2 | CURATIVE EFFECTIVENESS | 4 | 67% | 1% | 4 |
| 3 | MOPC 315 TUMOR | 4 | 36% | 1% | 8 |
| 4 | LIPOSOME ENCAPSULATED ADRIAMYCIN | 3 | 100% | 1% | 3 |
| 5 | ADRIAMYCIN INDUCED AUGMENTATION | 3 | 50% | 1% | 4 |
| 6 | MELPHALAN THERAPY | 3 | 60% | 1% | 3 |
| 7 | MICE BEARING | 2 | 13% | 3% | 16 |
| 8 | ADRIAMYCIN PLUS INTERLEUKIN 2 | 2 | 67% | 0% | 2 |
| 9 | LIBLOMYCIN | 2 | 50% | 1% | 3 |
| 10 | ADMINISTERED CYTOSTATIC DRUGS | 1 | 100% | 0% | 2 |
Journals |
Reviews |
| Title | Publ. year | Cit. | Active references | % act. ref. to same field |
|---|---|---|---|---|
| EFFECTS OF ANTICANCER DRUGS ON THE IMMUNE-SYSTEM IN HUMANS | 1989 | 70 | 61 | 72% |
| Immunopotentiation with low-dose cyclophosphamide in the active specific immunotherapy of cancer | 1998 | 66 | 46 | 39% |
| INTERPLAY BETWEEN THE TOXIC EFFECTS OF ANTICANCER DRUGS AND HOST ANTITUMOR IMMUNITY IN CANCER-THERAPY | 1987 | 30 | 34 | 71% |
| Immunomodulating anticancer alkylating drugs: Targets and mechanisms of activity | 2001 | 19 | 86 | 63% |
| OXAZAPHOSPHORINES AS BIOLOGICAL RESPONSE MODIFIERS - EXPERIMENTAL AND CLINICAL PERSPECTIVES | 1985 | 32 | 10 | 50% |
| Immunomodulation by anticancer chemotherapy: More is not always better (review) | 2001 | 24 | 92 | 35% |
| Combining cancer vaccines with chemotherapy | 2005 | 13 | 46 | 24% |
| Doxorubicin and paclitaxel enhance the antitumor efficacy of vaccines directed against HER 2/neu in a murine mammary carcinoma model | 2004 | 38 | 61 | 18% |
| INTRAVENOUS CYCLOPHOSPHAMIDE THERAPY OF SEVERE SLE | 1989 | 18 | 69 | 26% |
| Immunogenicity of anthracyclines: moving towards more personalized medicine | 2008 | 37 | 100 | 10% |
Address terms |
| Rank | Address term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
|---|---|---|---|---|---|
| 1 | CUALTOS | 1 | 30% | 0.5% | 3 |
| 2 | HEMATOPOIET DISORDERS | 0 | 17% | 0.2% | 1 |
| 3 | DUKE S CLIN | 0 | 13% | 0.2% | 1 |
| 4 | U 454 | 0 | 13% | 0.2% | 1 |
| 5 | BIOCHEM MOL BIOL MC 536 | 0 | 11% | 0.2% | 1 |
| 6 | INTEGRAT RECOGNIT IMMUNE SYST | 0 | 10% | 0.2% | 1 |
| 7 | CANC DRUG GRACE 347 | 0 | 100% | 0.2% | 1 |
| 8 | EXTREME BODY CONDIT STUDY | 0 | 100% | 0.2% | 1 |
| 9 | IMMUNOL INERNAL DIS | 0 | 100% | 0.2% | 1 |
| 10 | MICROBIOL IMMUNOL MC 790 BOX 6998 | 0 | 100% | 0.2% | 1 |
Related classes at same level (level 1) |
| Rank | Relatedness score | Related classes |
|---|---|---|
| 1 | 0.0000204872 | TUMOR BEARING STATE//AUTOIMMUNOTHERAPY//CD8 CELL REACTIVITY |
| 2 | 0.0000127118 | DITHIONITROBENZOATE//IGG BLOOD//YOSHIDA HEPATOMA |
| 3 | 0.0000126782 | DALTONS LYMPHOMA//FK 565//POLY PLAT |
| 4 | 0.0000111053 | ACUTE MORBILLI INFECTION//// |
| 5 | 0.0000095011 | TADEUSZ ORLOWSKI//MCGOOGAN LIB MED//ANTIBODY REPLACEMENT THERAPY |
| 6 | 0.0000090788 | OK 432//OK432//PROD LIFECYCLE MED INFORMAT |
| 7 | 0.0000089216 | WHOLE BLOOD CELL CULTURES//COLORIMETRY METHOD//HUMAN COLORECTAL TUMORS |
| 8 | 0.0000083422 | CYCLIC POLYLACTATE//RABDOMYOSARCOMA//CARCINOID SYNDROM |
| 9 | 0.0000081409 | FC 215//ACUTE HYPERSENSITIVITY PNEUMONITIS//HUMAN ANTIMURINE ANTIBODY |
| 10 | 0.0000076042 | IMEXON//1 4 DIHYDRO 2 3 QUINOXALINEDIONE//CYANOAZIRIDINE |